NDC properties for "Axiron 20 MG/ML Topical Solution" (RxCUI 1599948)
About this data
The tables show NDC propoerties for Axiron 20 MG/ML Topical Solution with the RxCUI 1599948
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for Axiron 20 MG/ML Topical Solution (RxCUI 1599948)
| MMSL_CODE | BD26663 |
|---|---|
| NDA | NDA022504 |
| RxCUI | 1599948 |
| SPL_SET_ID | 3b40e56a-51bb-4357-8861-325bb1195049 |
| Prescribable Synonym | Axiron 30 MG per 1.5 ML ACTUAT Topical Solution, 60 ACTUAT |
| RXNAV_STR | Axiron 20 MG/ML Topical Solution |
| RxNorm Name | 60 ACTUAT testosterone 30 MG/ACTUAT Topical Solution [Axiron] |
| RxNorm Synonym | Axiron 20 MG/ML Topical Solution |
| RxNorm Synonym | Axiron 30 MG per 1.5 ML ACTUAT Topical Solution |
| RxNorm Synonym | Axiron 30 MG per 1.5 ML ACTUAT Topical Solution, 60 ACTUAT |
| RxNorm Synonym | Axiron 30 MG/ACTUAT Topical Solution |
| Related queries | Interactions (for RxCUI 1599948) |
NDC Properties
NDC Item 00002197561
| NDC 9 | 0002-1975 |
|---|---|
| NDC 10 | 0002-1975-61 |
| NDC Item | 00002197561 |
| Packaging | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0002-1975-61) / 90 mL in 1 BOTTLE, WITH APPLICATOR |
| DCSA | CIII |
| FDA SPL set id | 327841 |
| Labeler | Eli Lilly and Company |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2019-01-31 |
| Marketing effective time low | 2010-11-23 |
| Marketing status | COMPLETED |
| NDA | NDA022504 |
| Related queries | Properties for NDC 9 0002-1975 |
NDC Item 00002197590
| NDC 9 | 0002-1975 |
|---|---|
| NDC 10 | 0002-1975-90 |
| NDC Item | 00002197590 |
| Packaging | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0002-1975-90) / 90 mL in 1 BOTTLE, WITH APPLICATOR |
| DCSA | CIII |
| FDA SPL set id | 327841 |
| Labeler | Eli Lilly and Company |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2019-01-31 |
| Marketing effective time low | 2010-11-23 |
| Marketing status | COMPLETED |
| NDA | NDA022504 |
| Related queries | Properties for NDC 9 0002-1975 |
NDC Item 00002197561
| NDC 9 | 0002-1975 |
|---|---|
| NDC 10 | 0002-1975-61 |
| NDC Item | 00002197561 |
| Packaging | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0002-1975-61) / 90 mL in 1 BOTTLE, WITH APPLICATOR |
| DCSA | CIII |
| FDA SPL set id | 327841 |
| Labeler | Eli Lilly and Company |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2019-01-31 |
| Marketing effective time low | 2010-11-23 |
| Marketing status | COMPLETED |
| NDA | NDA022504 |
| Related queries | Properties for NDC 9 0002-1975 |
NDC Item 00002197590
| NDC 9 | 0002-1975 |
|---|---|
| NDC 10 | 0002-1975-90 |
| NDC Item | 00002197590 |
| Packaging | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0002-1975-90) / 90 mL in 1 BOTTLE, WITH APPLICATOR |
| DCSA | CIII |
| FDA SPL set id | 327841 |
| Labeler | Eli Lilly and Company |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2019-01-31 |
| Marketing effective time low | 2010-11-23 |
| Marketing status | COMPLETED |
| NDA | NDA022504 |
| Related queries | Properties for NDC 9 0002-1975 |